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Summary
There is substantial evidence from preclinical data that the
antitumor cytotoxicity of selected chemotherapeutic agents
either alone or combined with radiation can be enhanced by
appropriate heat exposure (40–44 °C) of cells or tumor
tissues. Based upon these results the integration of hyper-
thermia as an additional treatment modality, given simultan-
eously with systemic chemotherapy or in combination with
radiochemotherapy, is currently tested at the clinic. Regional
hyperthermia combined with chemotherapy or radiochemo-
therapy showed impressive results (phase II studies) at
clinical relevant temperatures in locally advanced tumors of
different entities in terms of objective response rate, local
tumor control and relapse-free survival. Clinical protocols of
well-designed phase III trials on combined treatment moda-
lities integrating hyperthermia are rather limited but for some
tumors confirm its clinical benefit. In general, the clinical
approach to use hyperthermia has gained much more
interest within in the field of medical oncology. One of the
major reason is the substantial technical improvements
made with the available commercial equipment for local or
regional heating, especially in case of deep-seated lesions or
systemic heating. Further testing of the potential of hyper-
thermia combined with chemotherapy or radiochemotherapy
in prospective randomized trials are warranted. At this time,
hyperthermia as an adjunct to conventional treatment
strategies is recommended in the setting of clinical proto-
cols. The results of prospective trials should answer the
question for which types of local advanced or metastatic
tumors hyperthermia becomes standard as part of a multi-
modal treatment strategy.
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Zusammenfassung
Die Ergebnisse der präklinischen Forschung zeigen, daß die
therapeutische Effektivität ausgewählter Zytostatika sowie
deren Kombination mit Bestrahlung unter hyperthermen Be-
dingungen (40–44 °C) in Tumorzellen und Tumorgeweben
gesteigert wird. Auf dieser thermobiologischen Grundlage
wird derzeit im Bereich der Klinik die Integration einer Hyper-
thermie als zusätzliche therapeutische Möglichkeit mit simul-
tan applizierter systemischer Chemotherapie oder in Kombi-
nation mit Radiochemotherapie untersucht. Im Rahmen von
Phase-II-Studien wurde für die Thermochemotherapie und
Radiochemotherapie bei klinisch relevanten Temperaturen in
lokal fortgeschrittenen Tumoren verschiedener Entitäten
beeindruckende Resultate erzielt, wobei die objektive An-
sprechrate, die lokale Tumorkontrolle und das rezidivfreie
Überleben die wesentlichen Endpunkte darstellten. Klinische
Ergebnisse von prospektiv randomisierten Phase-III-Studien
unter Einbeziehung der Hyperthermie in multimodale Thera-
pieansätze liegen nur vereinzelt vor, zeigen aber für einige
Tumorentitäten einen deutlichen Vorteil zugunsten der Hyper-
thermie. Insgesamt ist im Bereich der internistischen Onko-
logie ein zunehmendes klinisches Interesse an der Hyper-
thermie festzustellen. Einer der wesentlichen Gründe ist der
technische Fortschritt im Bereich kommerziell erhältlicher,
ausgereifter Systeme zur lokalen bzw. regionalen Hyper-
thermie besonders für tiefliegende Tumoren oder Ganz-
körperhyperthermie. Eine weitere Überprüfung der Hyper-
thermie kombiniert mit systemischer Chemotherapie oder
Radiochemotherapie in prospektiven Phase-III-Studien ist
dringend notwendig. Zum jetzigen Zeitpunkt sollte die klini-
sche Anwendung der Hyperthermie als zusätzliche Maßnahme
zu konventionellen Behandlungsstrategien im Rahmen klini-
scher Protokolle erfolgen. Die Ergebnisse derartiger Studien
werden die Antwort geben, für welche Art von lokal fortge-
schrittenen oder metastasierten Tumorentitäten eine Hyper-
thermiebehandlung als Teil eines multimodalen Vorgehens
einen klinischen Standard darstellt.
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Introduction
The clinical application of hyperthermia with an increase of
tissue temperatures (range 40–44 °C) has been integrated into
multimodal anticancer strategies. This innovative treatment
approach within the field of medical oncology is based on the
evidence that hyperthermia enhances not only the radiosensi-
tivity of tumors, but also the therapeutic effects of anticancer
drugs, even in drug-resistant cells. Beside direct cytotoxicity of
heat and thermal enhancement of drug efficacy, hyperthermia
might be potentially useful to modulate the immune response
against heated tumor cells at moderate temperatures by in-
ducing the expression of heat shock proteins (HSP). Profound
research has produced a scientific basis for the simultaneous
application of hyperthermia in combination with ionizing radia-
tion and/or systemic chemotherapy. The rational for regional
hyperthermia (RHT) is based upon direct heat cytotoxicity and
thermal enhancement of radio- and/or chemosensitivity within
not well-perfused areas of the individual tumor. These areas
usually are hypoxic and drug supply is limited but reaching
highly effective temperatures (42–43 °C) due to low convec-
tion of heat. Whole-body hyperthermia (WBH) is usually
applied simultaneously with systemic chemotherapy to pa-
tients having metastatic disease with the intention of thermal
enhancement of drug sensitivity. This method is used not to
target the heating field to individual tumors but to increase the
core temperature of the patient’s body (range 40–41.8 °C). 
At present the combination of RHT and chemotherapy or
radiochemotherapy is administered within clinical protocols
(phase II/III) in order to improve local tumor control and re-
lapse-free survival in patients with high-risk, locally advanced
tumors of different entities. WBH is currently tested in phase
I/II protocols to evaluate feasibility and toxicity and to deter-
mine further the efficacy in patients with metastatic disease
refractory to conventional chemotherapy.
Thermobiology
Cell survival studies have shown that heat-induced cytotoxicity
is dependent on temperature and time of exposure. For an
isoeffect induced in a specific cell type or tissue by heating for
different times at different temperatures, a strong time–tem-
perature relationship exists, showing a large increase of cyto-
toxicity at higher temperatures (42.5–45 °C). Cells exposed to
more moderate temperatures (< 42.5 °C) are resistant to con-
tinuous heat exposure (2–4 h), which means they become
thermotolerant [1]. Thermotolerance can also be induced at
higher temperatures but its development requires time inter-
vals of approximately 6–12 h at 37 °C before second heat ex-
posure. The cellular status of thermotolerance is reversible and
is greatly diminished about 48–72 h after the triggering heat
dose has been applied. Thermosensitivity itself, but also the
development of thermotolerance are influenced by various
environmental parameters as pH, oxygen, nutritional supply,
but also by the proliferative status of cells [2, 3]. The target for
heat cytotoxicity is considered to be at the level of cellular
proteins [4]. Whether the major interaction of hyperthermia
and cellular proteins occurs at the level of the structure of
membranes, cytoplasm, cytoskeleton or nucleus, still is an open
question. One of the most exciting fields of thermobiology is
our better understanding of the so-called ‘thermal stress re-
sponse’ that relates to the early activation of heat shock genes
encoding the preferential synthesis of HSP [5]. Under normal
conditions and in response to stress, HSP are implicated in
protein–protein interactions such as folding, translocation and
prevention of inappropriate protein aggregation [6]. An
emerging field is the role of HSP in the stimulation fo the
immune response against cancer in which members of dif-
ferent HSP families (e.g. HSP70, HSP90-related glycoprotein
gp96) are involved [7]. When purified from cells, it has been
shown that they are associated with a broad range of peptides
derived from that particular cell, such that the HSP chaperon
the antigenic repertoire of the cells from which they are puri-
fied [8]. Immunotherapy of mice with preexisting cancers using
HSP preparations derived from autologous cancer resulted 
in retarded progression of the primary cancer, a reduced
metastatic load, and a prolongation of the life-span [9]. The
role of HSP may be also interesting in that the heat-inducible
HSP70 expressed on the cell surface of certain tumor cells acts
as positive recognition signal for natural killer (NK) cells [10].
Therefore, beside direct cell cytotoxicity, hyperthermia has 
the additional potential for use in immunotherapy in clinical
applications.
Heat and Chemotherapy Interaction
By combining heat exposure with anticancer drugs, a coopera-
tive effect can be observed, dependent on the specific chemo-
therapeutic agent. In general, selected cytotoxic drugs showed
an enhanced inhibition of clonogenic cell growth in vitro at
higher temperatures. The magnitude of the thermal enhance-
ment ratio (TER), which is defined as the ratio of the dose of a
drug causing a given level of cell death in the presence of ab-
sence of hyperthermia, depends on the treatment temperature,
time of exposure and drug concentration. Excellent reviews on
the interaction of hyperthermia with a wide range of antican-
cer agents in models employing cells in tissue culture or rodent
tumors have been presented by Hahn [11], Dahl [12] and Urano
[13]. Despite the complexity of the underlying mechanisms for
the observed thermal enhancement, the phenotype of inter-
action can be classified into 3 categories using isobologram
analysis of in vitro data [14]: 1. independent; 2. additive; 
3. synergistic. The term noninteractive (= independent) de-
scribes a situation in which hyperthermia and the individual
drug appear to act by independent mechanisms. For some
agents, the slope of the survival curve changes smoothly with
continuously increasing temperature, meaning that hyper-
thermia results in the additivity of damage by increasing the
cytotoxic mechanism (= additive). A third group of drugs
shows distinct threshold effects: little or no sensitization at low
temperatures, but marked sensitization occurring at 42 °C or
higher (= synergistic). The classification for selected anti-
cancer drugs whose modes of action fall into one of these cate-
gories is shown in table 1.
Antimetabolites (e. g. 5-fluorouracil, methotrexate) do not
seem to be the optimal candidates for combination with hyper-
thermia because the combined effect of heat and drug expo-
sure upon cell survival is equal with the effect of each individ-
ual treatment alone (= independent action). In addition, both
taxanes (paclitaxel and docetaxel) did not show any significant
thermal enhancement of cytotoxicity using different time inter-
vals between the administration of taxanes and hyperthermia.
The efficacy of alkylating agents (e.g. cyclophosphamide,
ifosfamide and melphalan) but also of the nitrosoureas (e.g.
BCNU) was enhanced by hyperthermia, both in vitro and in
vivo. Maximal effects occurred when the agents were sched-
uled simultaneously with hyperthermia in vitro (endpoint:
clonogenic survival) and immediately before hyperthermia in
vivo (endpoint: tumor growth delay). In vivo the TER was the
same for temperatures between 40.5–42.5 °C, with only a slight
increase at higher temperatures of 42.5–44.5 °C. The impor-
tance of appropriate timing and sequencing for the evaluation
of heat and drug interaction was recently shown for gemcita-
bine (= 2’,2’-difluorodesocycytidine). Simultaneous application
led to decreased cytotoxicity, whereas an interval of 24 h be-
tween dFdCyd and hyperthermia led to an enhanced cell
killing [15]. For cisplatin (CCDP) and analogues (e.g. carbo-
platin) a potentiating effect of hyperthermia on cytotoxicity
has been demonstrated already at relatively low temperatures
of 40.5 °C. Overcoming chemoresistance has been extensively
studied within the past, especially using CDDP-resistant cells
[16]. In regard to the potential benefit that drug-resistant cells
can be recruited for effective therapy by combining chemo-
therapy with hyperthermia, it was important to show that
chemoresistance against several anticancer drugs (e.g. mito-
mycin C, anthracyclines, BCNU, melphalan) including CDDP
could be reversed at least partially by the addition of heat [17].
The effect of thermotolerance and its interference with drug
sensitivity of cells is still controversially discussed. However,
hyperthermia did not induce cellular p-glycoprotein expression
[18], and heat sensitivity of human leukemia clones displaying
multidrug resistance was not altered [19]. In conclusion, there is
substantial evidence from preclinical data that the antitumoral
cytotoxicity of selected chemotherapeutic agents can be en-
hanced by appropriate heat exposure to cells or tumor tissues.
Clinical Application
First, clinical hyperthermia can be divided into two almost
separate domains: WBH versus RHT. The clinical application
of heat can be induced by electromagnetic field technique,
ultrasound, or perfusion methods. Lately, noninvasive WBH
can be administered with an Aquatherm radiant heat device
(Cancer Research Institute, New York, NY, USA), achieving
systemic temperatures up to 41.8 °C [20]. At present nonin-
vasive RHT is most commonly performed using single micro-
wave or ultrasound applicators for superficial hyperthermia
and arrays of multiple applicators for deep heating [21]. Pref-
erential heating of different tumor regions is achieved by the
lower convection of heat from relatively poorly vascularized
areas of tumors compared to their surrounding tissues. During
hyperthermia treatments the measurement of the actual tem-
perature distribution in the tumor or immediately adjacent
tissue is crucial to the clinical evaluation of the quality of RHT
[22]. So far, noninvasive methods for temperature measure-
ments in deep-seated tissues are under investigation [23]. From
temperature measurements acquired as temperature versus
time and temperature versus depth plots, time-averaged tem-
peratures can be calculated at each site monitored. In addition,
the time-averaged temperatures above 20, 50 and 90% of the
monitored points (reported in terms of T20, T50, and T90) allow
comparison of different RHT treatments in clinical protocols
with regard to the quality of heating [24]. More recently, the
clinical application of the thermal isoeffect dose (TID) con-
cept has been applied in retrospective analysis of clinical data
to guide future clinical studies in which different treatment
protocols for different times at different temperatures are con-
verted into equivalent minutes at 43 °C (EM43) [25].
Regional Hyperthermia Combined with Radiation
Within the past, the most often performed treatment modality
involving hyperthermia was its local or regional application
with radiation. Now substantial clinical data exist, demonstrat-
ing for the treatment of locally advanced superficial tumors of
different entities the improved efficacy and relative lack of nor-
mal tissue toxicity of combined radiation and hyperthermia
treatments as compared to radiation therapy alone [26]. In
addition to the results of numerous phase II studies, more re-
cently the results of European phase III randomized multi-
center trials became available. For example, in superficial
tumors, an advantage of the combined treatment was shown for
recurrent or metastatic melanoma [27] and recurrent breast
cancer [28]. In melanomas there was an increase in complete
response (CR) or 35–62% with an 2-year local control rate of
28 versus 46%. The overall 5-year survival rate was 19%, but
38% of the patients for whom all known disease was con-
trolled, survived 5 years. The cooperative study of the Medical
Research Council (MRC, UK) and the Princess Margaret
Hospital (Ontario, Canada) demonstrated in recurrent breast
cancer an increase in CR of 41–59% with a 2-year control rate
from 20 to 50%, but no statistical difference in overall survival.
Regional Hyperthermia Combined with 
Chemotherapy
In the last few years radiation therapists start to accept RHT
as an useful adjunct to their modality, motivated largely by 
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Table 1. Interaction between hyperthermia and anticancer drugs
Independent Additive Synergistic
5-Fluorouracil doxorubicin cisplatin
Methotrexate mitoxantrone carboplatin
Actinomycin D cyclophosphamide mitomycin C
Cytarabine ifosfamide bleomycin
Taxanes melphalan
BCNU
gemcitabine
the results of these studies. Completed clinical protocols on
the combination of RHT and chemotherapy are rather limited,
but this approach has now gained much more interest within
the field of medical oncology. One of the main reasons are 
the substantial technical improvements made in available
commercial equipment for local or regional heating especially
for deep-seated lesions and for systemic heating. Another
reason is related to the more general acceptance of using multi-
modal strategies in the treatment of locally advanced cancers
in order to obtain optimal local control and to prevent distant
metastases. The advanced stages (e.g. T3/4 N1/2) or tumors in
unfavorable anatomic locations often prevent primary resec-
tion with adequate margins, and the toxicity of radiotherapy
limits the use of potentially therapeutic doses. Therefore,
based on the benefits of heat-induced enhancement of drug-
efficacy, the integration of RHT as an additional treatment
modality given simultaneously with systemic chemotherapy is
currently used in the clinic.
RHT given as an adjunct to systemic chemotherapy has been
proven feasible with promising results in phase II trials. In
table 2 results are given of several selected studies which have
been extended to well-designed phase III trials already
started, mainly in Europe. The most relevant aspects of these
trials and further applications of thermochemotherapy for
different tumor types will be discussed below.
Stomach and Pancreatic Cancer
Multi-institutional studies on clinical RHT combined with
chemotherapy of stomach and pancreatic cancers have been
performed in Japan using an 8-MHz-radiofrequency heating
device (Thermotron RF8, Yamamoto Co., Osaka, Japan). 
This system most commonly used for hyperthermia in Japan
achieves temperatures within the range of 40–43 °C in deep-
seated tumors [29]. A total of 33 patients with stomach cancer
(29 of them stage IV) and of 22 patients with pancreatic cancer
(stage III/IV) received RHT twice weekly combined with
mitomycin C and 5-fluorouracil [30]. Primary tumor response
was 39% (3 CR/10 PR, partial response) and 36% (3 CR/5 PR),
respectively. In addition, objective complaints (e.g. abdominal
pain, ascites, passage disturbance, nausea, vomiting) were im-
proved in 66% of all cases. Although follow-up was limited,
among pancreatic cancers 2 patients survived disease-free
longer than 30 months and 4 patients were still alive with no
regrowth of tumors. These results and also the promising
results reported by Shibamato et al. [31] using thermoradio-
therapy in nonresectable pancreatic cancer warrant further
clinical investigation.
Soft-Tissue Sarcomas and Bone Tumors
First results were obtained from a phase II study comprising 
38 adult patients mainly with soft-tissue sarcomas [32]. These
patients had relapsed after prior surgery and radiation and had
not responded to previously given chemotherapy alone. The
local response rate was 37%. A drug combination of ifosfamide
and etoposide (VP 16) has been used combined with RHT as
second-line treatment. Beside long-term tumor control in
some of the patients, the analysis of tumor temperatures (e.g.
T20, T50, T90) achieved with the BSD system showed signifi-
cant higher temperature parameters in responders versus non-
responders, respectively. These results were confirmed in an
extended trial recruiting 65 patients with chemopretreated
sarcomas [33]. The consecutive phase II protocol (RHT-91)
was designed as a neoadjuvant study where the EIA regimen
(etoposide + ifosfamide + adriamycin) was given to 59 patients
with high-risk soft-tissue sarcomas (size > 8 cm, grade II/III,
extracompartimental) for 4 cycles prior to surgical resection.
After first initial analysis showing no severe toxicity or un-
expected treatment side effects [34], the evaluation of clinical
and pathohistological response was 47%. At present, 29 pa-
tients are alive and the median follow-up of all patients is more
than 3.5 years. The estimated rate of the 5-year overall survival
is 46% [35]. Further, the EORTC Soft Tissue And Bone
Sarcoma Group (STBSG) is testing this multimodal concept as
a first-line treatment of high-risk soft-tissue sarcomas in adults
in a multicenter prospective randomized phase III trial
(EORTC 62961 / ESHO RHT-95) as an intergroup study with
the European Society of Hyperthermic Oncology (ESHO).
Patients meeting all of the eligibility criteria at first presenta-
tion (tumor size ‡ 5 cm, grade II or III, extracompartimental)
or in addition after inadequate surgery (resections with
microscopic/macroscopic residual tumor) will receive neoadju-
vant chemotherapy either combined with or without RHT.
WBH achieved by reinfusion of extracorporeal heated blood
combined with ifosfamide and carboplatin (CBDCA) showed
6 PR in 19 patients with metastatic disease [36]. In a conse-
cutive phase II study the ICE regimen (ifosfamide + carbo-
platin + etoposide) was given. In 12 sarcoma patients with
distance disease, 7 partial responses were observed [37]. Non-
invasive WBH achieved with an Aquatherm radiant heat
device has been combined with carboplatin in patients with
refractory cancers [38]. It is noteworthy that WBH did not
affect the pharmacokinetics of carboplatin in that trial. Also,
in repeated pair courses, there was no significant difference in
the myelosuppression caused by carboplatin with or without
WBH. More recently, the application of melphalan and WBH
at 41.8 °C for 60 min was well tolerated and the clinical results
served as the basis to further elucidate the potential role of
WBH as and adjunct to systemic chemotherapy in advanced
cancer patients [39].
Pediatric Cancers
The application of regional hyperthermia as part of combined
modality therapy in pediatric patients, especially with tumors
that failed to respond to standard regimen, has been proven
feasible with several drug combinations. A multicenter study
of the German Society of Pediatric Oncology and Hematology
(GPOH) recruited 34 patients (mean age 11 years) mainly with
deep-seated advanced soft-tissue sarcomas and Ewing tumors.
Among 25 patients with locally advanced tumors, 12 patients
of this group achieved no evidence of disease (NED), in-
cluding 7 patients with CR [40]. Follow-up of these patients
showed long-term tumor control ranging from 7 to 64 months.
RHT in combination with cisplatin-based systemic chemo-
therapy in recurrent of refractory extracranial nontesticular
germ cell tumors of children and adolescents was found to
induce objective tumor response in 70% of patients.
In comparison to a matched cohort, the probability of event-
free survival was shown to be superior for these patients [41].
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The results so far are encouraging and the study has been ex-
tended to patients with a poor response to first-line treatment.
Cervial Cancer
Recurrences of carcinoma of the uterine cervix develop in al-
most half of the patients treated for primary invasive cervical car-
cinoma (Figo stage IIIb/IVa). The majority of these recurrences
occur without distant metastases in the pelvis. In this situation,
radiotherapeutic or surgical treatment is seldom an option, be-
cause most of the patients have already received radiotherapy
and very few are suitable for exenterated surgery. In a phase II
trial performed within the Amsterdam Gynecologic Oncology
Group (AGOG), 23 patients with previously irradiated recur-
rent carcinoma of the uterine cervix received weekly RHT and
cisplatin [42]. The response rate was 52%, median duration of
response 9.5+ months and the 1-year survival 42%. The overall
toxicity was moderate. The fact that 25% of the responding
patients were able to undergo salvage surgery was also encour-
aging. Therefore, a prospective randomized trial comparing
weekly RHT and cisplatin with cisplatin alone has been ini-
tiated in cooperation with several European institutions.
Regional Hyperthermia Combined with 
Radiochemotherapy
An extension of multimodal therapy concepts incorporating
hyperthermia is its combination with radiation and chemo-
therapy (‘triple modality’), which seems to be feasible and
effective as tested in several phase I/II trials. A few examples
of trimodality studies should be discussed for the tumor
entities given in table 3.
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Table 2. Hyperthermia combined with chemotherapy
Authors/Reference Study Entity Number Hyperthermia Chemotherapy Results
of patients
Kakehi et al. phase II stomach cancer 33 RHT/Thermotron mitomycin + 5FU 3 CR + 10 PR (39%)
1990 [30] pancreatic cancer 22 8 MHz mitomycin + 5FU 3 CR + 5 PR (36%)
Issels et al. phase II (RHT 86) sarcomas (pretreated with 38 RHT/BSD 1000 VP 16 + IFO 6 pCR + 4PR + 4 FHR (37%)
1990 [32] follow-up chemotherapy) 60–110 MHz
1991 [33] sarcomas (pretreated with RHT/BSD 1000 
chemotherapy) 65 60–110 MHz VP 16 + IFO 9 pCR + 4 PR + 8 FHR (32%)
1998 [35] phase II (RHT 91) high-risk soft-tissue sarcomas 59 RHT/BSD 2000 VP 16 + IFO + ADR 1 CR/6 pCR + 8 PR + 13 MR 
80–110 MHz (= EIA) (47%) OS: 46%
phase III high-risk soft-tissue sarcomas 44 RHT/BSD 2000 EIA ± RHT (12/98)
(EORTC 62961) 80–110 MHz (randomized)
Eggermont et al., phase II soft-tissue sarcomas 55 ILP TNF + IFN + L-PAM 10 CR/35 PR (87%)
1996 [52]
Wiedemann et al., phase I/II sarcomas teratomas 19 WBH IFO + CBDCA 6 PR (32%)
1994 [36] (metastatic)
Wiedemann et al., phase II sarcomas (metastatic) 12 WBH IFO + CBDCA + 7 PR (58%)
1996 [37] VP 16
Robins et al., phase I refractory cancers 16 WBH/Aquatherm L-PAM 1 CR/2 PR (19%)
1997 [39] (advanced or metastatic) (dose-escalation)
Romanowski et al., phase II pediatric sarcomas 34 RHT/BSD 2000 VP 16 + IFO + 12 NED (‘best response’)/7 CR 
1993 [40] 80–110 MHz CBDCA (duration: 7–64 months)
Wessalowski et al., phase II pediatric non-testicular 10 RHT/BSD 2000 CDDP + VP 16 + 5 CR + 2 PR (70%) 6 patients 
1998 [41] germ cell tumors 80–110 MHz IFO (= PEI) alive without evidence of 
tumor (10–33 months)
Rietbroek et al., phase II cervical cancer 23 RHT/array system CDDP (weekly) 2 pCR/1 CR + 9 PR (52%)
1997 [42] (recurrences) 70 MHz
Schilthuis et al., phase III cervical cancer 5 RHT/array system CDDP ± RHT ongoing study
1998 (ESHO 97-1) (recurrences) 70 MHz (randomized)
RHT = Regional hyperthermia; EIA = etoposide + ifosfamide + adriamycin; ILP = isolated limb perfusion; WBH = whole-body hyperthermia; 5FU = 5-fluorouracil; 
VP 16 = etoposide; IFO = ifosfamide; ADR = adriamcyin = doxorubicin; CDDP = cisplatin; CBDCA = carboplatin; Bleo = bleomycin; L-PAM = melphalan; 
TNF = tumor necrosis factor-a; IFN = interferon-g; p = pathohistological; CR = complete remission; PR = partial remission; MR = minor response; 
FHR = favorable histological response > 75%; OS = overall survival; NED = no evidence of disease.
Cancer of the Esophagus
From 1990 to 91 40 patients with locally advanced squamous
cell carcinoma of the esopagus were treated with preoperative
chemotherapy (bleomycin + cisplatin) either combined with
(n = 20 patients) or without (n = 20 patients) hyperthermia in a
prospective trial using a radiofrequency endotract electrode.
Objective tumor regression, histopathological effectiveness of
the preoperative regimen and improvement of dysphagia were
substantially better in the treatment arm combined with hyper-
thermia [43]. However, the number of pathological CR with
no viable cancer cells in the resected specimens were signifi-
cantly increased when preoperative radiotherapy was also
used in addition to thermochemotherapy (‘triple modality’) as
has been shown in previous trials [44, 45].
Head and Neck Cancer
On the basis of the experience in hyperthermia-combined
treatment of nodal metastases from head and neck cancer with
the addition of either cisplatin or radiotherapy, the Radio-
therapy Department of Trento (Italy) performed a phase II
study on this disease using trimodal therapy combining hyper-
thermia, conventionally fractionated radical radiation and
weekly low-dose infusion of cisplatin [46]. In 16 out of 18 pa-
tients treated in such a way, objective tumor response was 89%
(13 CR / 3 PR) and acute local toxicity was mild. The trimodal
therapy deserves further evaluation as a way to enhance the
efficacy of radiation and chemotherapy for local control.
Rectal Cancer
In rectal cancer, resection with negative margins is the major
tool for achieving long-term survival. However, in locally
advanced tumors (UICC stages II/III) local recurrences after
surgery alone have been reported in up to 58% of patients
[47]. For recurrent rectal cancer the prognosis is poor [48].
Efforts to improve the treatment results of locally advanced
rectal cancers include preoperative radiotherapy or combined
radiochemotherapy. Preoperative radiotherapy for locally
advanced rectal carcinomas improved the resectability rate
and the duration of local control [49, 50]. To further intensify
preoperative radiotherapy different regimens of combined
chemotherapy and hyperthermia have been tested, showing
encouraging results when compared with radiation or chemo-
therapy alone in historical controls. For example, in a pro-
spective phase II study 37 patients with local advanced rectal
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Table 3. Hyperthermia combined with radiochemotherapy
Authors/Reference Study Entity Number Hyperthermia Radio- Results
of patients chemotherapy
Sugimachi et al., phase II/III oesophagus carcinoma 53 LHT/Endoradiotherm 32 Gy + Bleo 7 pCR (27%) with RHT (n = 27)
1992 [44] (preoperative) 13–56 MHz (3 weeks) 2 pCR (8%) without RHT (n = 20)
Amichetti et al., phase I/II head and neck cancer 18 LHT/BSD-MA 150 70 Gy + CDDP 13 CR + 3 PR (89%)
1993 [46] (N2/N3) 280–300 MHz (7 weeks)
Rau et al., phase II rectum carcinoma 37 RHT/BSD 2000 45 Gy + 5FU/Lv 5 pCR (14%) + 17 PR (46%)
1998 [51] (preoperative) 90 MHz (4 weeks)
Rau et al., phase III rectum carcinoma 100 RHT/BSD 2000 45 Gy + 5FU/Lv ongoing study
1998 [51] (preoperative) 90 MHz (4 weeks) ± RHT 
(randomized)
LHT = Local hyperthermia; RHT = regional hyperthermia; Bleo = bleomycin; CDDP = cisplatin; 5FU = 5-fluorouracil; Lv = leucovorine; p = pathohistological; 
CR = complete remission; PR = partial remission.
High-Risk Groups
S1 = Primary tumor ‡ 5 cm, GII/III, deep and extracompartmental
S2 = Local recurrence of S1 tumor or any type of local recurrence deriving from primary STS 
with all of S1 features
S3 = Inadequate surgery of S1 or S2 tumor
For information please call study co-ordinator,
phone +49-89-70 95-47 68.
Randomization according to stratification criteria
Arm A: EIA + RHT
4 cycles
Arm A: EIA + RHT
4 cycles
Progressive disease;
MAJOR protocol violation
Arm B: EIA
4 cycles
Arm B: EIA
4 cycles
Off-study
13th week: restaging,
evaluation of response
Responder:
CR, PR
or
stable disease
Definitive
surgical resection;
pathohistological evaluation
Radiation
Follow-up
Call
study center
Fig. 1. EORTC 62961/ESHO RHT-95: High-risk soft-tissue sarcoma study;
for information please call study co-ordinator, phone +49-89-70 95-47 68.
cancer (T3/T4) were treated with preoperative regional hyper-
thermia combined with radiochemotherapy [51]. The trimodal
treatment was generally well tolerated. The overall resect-
ability rate was 89%. The histopathological report confirmed
no evidence of residual tumor in 5 resected specimens (5 pCR)
and downstaging > 50% of the tumor size as documented by
CT or endorectal ultrasound in another 17 patients (17 PR).
The survival rate after 38 months was 86% and none of the
31% of patients with negative margins (R0 resection) showed
local recurrence, but 5 patients developed distant metastases.
The contribution of regional hyperthermia to locoregional
tumor control and overall survival within this preoperative
setting is now to be proven in an ongoing phase III trial
initiated by the same study group.
Conclusion
The distribution of temperatures (range 40–44 °C) achieved 
in human tumors by regional hyperthermia is heterogeneous
mostly dependent on blood supply and tumor-specific par-
ameters. Based upon preclinical investigations, the effects of
hyperthermia are mainly due to enhancement of drug efficacy
or thermal radiosensitization, and to a lower extent to direct
cytotoxicity within areas of tumors heated up to more than
42.5 °C. The technical application of RHT is feasible and effec-
tive if combined with chemotherapy or radiochemotherapy, as
shown in several clinical studies. Phase II/III trials showed im-
pressive results at clinically relevant temperatures in locally
advanced tumors of different entities in terms of objective
response rate, local tumor control, and relapse-free survival.
Further testing of the potential of regional hyperthermia
combined with either of these modalities in prospective ran-
domized trials is warranted.
The clinical experience using WBH is limited to first results of
phase I/II studies but needs further evaluation in terms of toxi-
city and proven efficacy in metastatic disease not responding
to first-line chemotherapy.
In general, hyperthermia as an adjunct to conventional treat-
ment strategies can only be recommended in the setting of
clinical protocols. The results of prospective trials should
answer the question whether hyperthermia becomes standard
as part of a multimodal strategy for the treatment of high-risk
patients with locally advanced or metastatic tumors.
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